Truist Financial Lowers Boston Scientific (NYSE:BSX) Price Target to $92.00

Boston Scientific (NYSE:BSX) had its target price reduced by stock analysts at Truist Financial from $95.00 to $92.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the medical equipment provider’s stock. Truist Financial’s target price would suggest a potential upside of 31.36% from the company’s current price.

A number of other brokerages have also recently weighed in on BSX. Canaccord Genuity Group dropped their price target on Boston Scientific from $112.00 to $109.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. The Goldman Sachs Group set a $99.00 target price on shares of Boston Scientific in a report on Thursday, February 5th. BTIG Research reissued a “buy” rating on shares of Boston Scientific in a research report on Wednesday, February 4th. Sanford C. Bernstein restated an “outperform” rating and set a $112.00 price target on shares of Boston Scientific in a report on Friday, February 6th. Finally, Robert W. Baird reduced their price target on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $107.18.

Boston Scientific Price Performance

NYSE BSX opened at $70.04 on Wednesday. Boston Scientific has a 1 year low of $67.56 and a 1 year high of $109.50. The business’s fifty day moving average is $80.31 and its two-hundred day moving average is $92.40. The stock has a market capitalization of $103.93 billion, a P/E ratio of 36.10, a P/E/G ratio of 1.00 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. The business had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company’s revenue was up 15.9% compared to the same quarter last year. During the same period last year, the company posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, research analysts forecast that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insider Activity at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.50% of the company’s stock.

Institutional Investors Weigh In On Boston Scientific

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BSX. Norges Bank acquired a new stake in Boston Scientific during the fourth quarter valued at $2,199,395,000. Edgewood Management LLC acquired a new position in Boston Scientific in the 2nd quarter worth about $746,655,000. Parnassus Investments LLC raised its stake in shares of Boston Scientific by 42,978.9% during the 3rd quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock worth $672,128,000 after purchasing an additional 6,868,459 shares in the last quarter. Egerton Capital UK LLP raised its stake in shares of Boston Scientific by 223.7% during the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock worth $518,660,000 after purchasing an additional 3,671,548 shares in the last quarter. Finally, Maverick Capital Ltd. acquired a new stake in shares of Boston Scientific during the 4th quarter valued at about $280,735,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysts still show support: Truist trimmed its price target (from $95 to $92) but kept a “buy” rating, signaling continued conviction in BSX’s medium‑term upside. Truist lowers price target
• Positive Sentiment: Market commentary highlights Boston Scientific as a defensive, highly rated healthcare stock—helpful positioning if macro/commodity volatility rises. The Highest-Rated Healthcare Stock to Buy Now
• Neutral Sentiment: Broader health‑care weakness: the NYSE Health Care Index was softer late Thursday, weighing on names including BSX. Sector Update: Health Care Stocks Softer
• Neutral Sentiment: Relative underperformance note: MarketWatch flagged BSX as underperforming peers during the session, which can amplify selling flows even absent company‑specific new data. Boston Scientific Corp. stock underperforms Thursday
• Negative Sentiment: Recall expanded: Boston Scientific amended its Accolade pacemaker recall; the affected population is now ~1.6 million devices — a clear near‑term operational and reputational headwind. Market Chatter: Boston Scientific Amends Recall
• Negative Sentiment: Investigative report: The New York Times reports Boston Scientific knew of pacemaker battery problems for years and an internal 2025 test found extremely high failure rates — this raises potential regulatory, replacement, and liability risks. Boston Scientific Knew of Pacemaker Battery Problems for Years
• Negative Sentiment: Legal overhang: multiple securities‑class‑action complaints and numerous law‑firm investor alerts have surfaced, creating ongoing litigation risk and potential settlements/expenses. Rosen Law Firm investor alert
• Negative Sentiment: Street view trimmed: UBS lowered expectations for BSX, adding to the negative analyst chatter that can pressure sentiment. UBS lowers expectations

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.